回生口服液维持治疗对中晚期非小细胞肺癌生存质量及无进展生存期的影响  

Effect of maintenance therapy with Huisheng Oral Liquid for patients in mid-advanced non-small cell lung cancer

作　　者：杜军华 尹宜发 乔洪源[2] 

机构地区：[1]宜昌市第二人民医院肿瘤放化疗科,湖北宜昌443000 [2]三峡大学第二人民医院肿瘤放化疗科,湖北宜昌443000

出　　处：《临床荟萃》2015年第6期641-644,共4页Clinical Focus

摘　　要：目的探讨中药回生口服液维持治疗对中晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者卡氏(KPS)评分、生存质量及无进展生存期(progression-free survival,PFS)的影响。方法根据入组标准选取76例中晚期NSCLC患者,随机分为治疗组42例与对照组34例。治疗组给予回生口服液维持治疗,对照组给予对症支持治疗,并利用Kaplan-Meier方法,对患者PFS进行统计分析。结果入组76例,出组2例,可评价疗效74例,两组临床基线资料分布均衡(P>0.05),两组患者临床证候及体力状况改善差异有统计学意义(P<0.05)。除社会家庭状况(SPW)和与医生关系(RD)外,两组维持治疗前后生活质量评分差值差异有统计学意义(P<0.05)。生存分析显示治疗组和对照组PFS分别为5.5月、4.2月(P<0.05)。结论中药回生口服液维持治疗可提高中晚期NSCLC患者KPS评分,改善患者生活质量,延长患者PFS。Objective To evaluate the quality of life,KPS score and progression-free survival （PFS）after traditional Chinese medicine compound Huisheng Oral Liquid therapy in patients with mid-advanced non-small cell lung （m-ANSCLC）cancer.Methods Seventy-six patients with m-ANSCLC were randomly assigned to two groups,42 patients in the treatment group received Huisheng Oral Liquid,and the other 34 patients in the control group got support treatment for the disease signs.Kaplan-Meier analysis was used to evaluate PFS.Results There were 74 patients included in the trial and 2 patients excluded.Baseline characters between two groups were not significant different （P〉0.05 ）.The quality of life and KPS score between two groups had statistically different（P 〈 0.05 ）. Except social family status（SPW）and relationship with the doctor（RD）,the other aspects between two groups showed statistically significant difference（P 〈0.05）.Median PFS of the treatment group and control group were 5.5 months and 4.2 months,respectively.Conclusion Maintenance treatment by Huisheng Oral Liquid can elevate KPS score, improve the quality of life,prolong PFS in m-ANSCLC patients.

关 键 词：癌 非小细胞肺 无病生存 回生口服液 

分 类 号：R734.2[医药卫生—肿瘤]